Delving into the Latest Updates on Ferring Pharmaceuticals Ltd. with Synapse

A prospective, randomised study comparing a 3-sachet Picolax® treatment with the standard 2-sachet Picolax® for bowel cleansing prior to colonoscopy. - Picolax® 2- .v. 3-Sachet

开始日期2008-11-24

申办/合作机构

Ferring Pharmaceuticals Ltd.

100 项与 Ferring Pharmaceuticals Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Ferring Pharmaceuticals Ltd. 相关的专利（医药）

登录后查看更多信息

3

项与 Ferring Pharmaceuticals Ltd. 相关的文献（医药）

2023-03-01·Therapeutic Innovation & Regulatory Science

Publisher Correction: Survey Result for E-labeling Initiatives in Asia

作者: Padhye, Anagha ; Mo, Runyi ; Matsui, Rie ; Yamaguchi, Koji ; Chee, Alice Seat Mee ; Quizon, Paul Marvin ; Harnpramukkul, Usanee ; Seo, Jeong-Min ; Lee, Jadz Jevz Venzon ; Nguyen, Thuy ; Khairilisani, Destita ; Ting, Ivy ; Sem, Ellen ; Chang, Jenny ; Park, Ina

2023-03-01·Therapeutic Innovation & Regulatory Science

Survey Result for E-labeling Initiatives in Asia

Article

作者: Padhye, Anagha ; Mo, Runyi ; Matsui, Rie ; Yamaguchi, Koji ; Chee, Alice Seat Mee ; Quizon, Paul Marvin ; Harnpramukkul, Usanee ; Seo, Jeong-Min ; Lee, Jadz Jevz Venzon ; Nguyen, Thuy ; Khairilisani, Destita ; Ting, Ivy ; Sem, Ellen ; Chang, Jenny ; Park, Ina

AbstractUnder the COVID-19 pandemic, various electronic labeling initiatives have accelerated worldwide in the healthcare and pharmaceutical fields as part of a wider digital transformation [1, 2]. Although there is no universal definition of electronic labeling (e-labeling) globally, it is widely understood that e-labeling refers to the product information that is distributed via electronic means. There are 5 factors to be considered in e-labeling, and these are discussed in this publication. APAC is an industry-driven initiative with 13 R&D-based pharmaceutical associations joining from 11 markets in Asia. e-labeling was discussed as a new topic starting in 2020, and a 22-question survey was conducted in November 2021 to understand the current e-labeling status. The survey results showed that e-labeling initiatives were at different levels of maturity in the Asian region, although most markets have started to discuss e-labeling initiatives. Various challenges exist around e-labeling initiatives due to a variety of different approaches being taken in the region. It would be advisable to develop regional guidance on how to proceed with e-labeling initiatives in the Asian region to have a consistent and efficient approach. The close collaboration between agencies, Health Care Professionals (HCPs), patients, and industry associations is important to move e-labeling initiatives forward in Asia.

1978-04-01·Clinical Science

Structure—Activity Relations of the Fibrinolytic Response to Vasopressins in Man

Article

作者: Cort, J. H. ; Cash, J. D. ; Gader, A. M. A. ; Mulder, J. L.

1. The systemic plasminogen activator response has been examined after intravenous infusion of the following peptides related to neurohypophyseal hormones in approximately equimolar dosages into informed, consenting human volunteer subjects: (a) the natural nonapeptides: lysine- and arginine-vasopressin, oxytocin and arginine-vasotocin, (b) the N- and C-terminal tripeptide fragments of vasopressin and (c) four vasopressin analogues without pressor activity, altered at the N-terminus, the disulphide bridge and/or sequence position 8 in the C-terminal tripeptide. In addition, angiotensin II and adrenaline were infused.2. It was observed that some of the cyclic nonapeptides resulted in high and prolonged increases in amounts of plasminogen activator in venous blood, in the following order, both for amplitude and duration: 1-desamino-6-monocarba-[8-d-arginine]-vasopressin > 1-desamino-[8-d-arginine]-vasopressin ≫ arginine-vasopressin = lysine-vasopressin > Nα-glycyl-glycyl-glycyl-lysine-vasopressin.3. No plasminogen activator responses followed infusions of vasopressin tripeptide fragments, oxytocin, angiotension II, 1-desamino-[8-N-MeArg]-vasopressin or 9-desglycineamide-lysine-vasopressin octapeptide.4. Mole for mole, the four most active substances were approximately two orders of ten more potent than adrenaline by amplitude comparison alone.5. Intra-arterial adrenaline, in one-tenth the systemic dose, stimulated a release of plasminogen activator from the infused local vascular bed only, This did not occur with equivalent doses of arginine-vasopressin and 1-desamino-[8-d-arginine]-vasopressin.6. It is concluded that plasminogen activator release arising from catecholamine-responding and vasopressin-responding receptors are both molecule-specific and different in anatomical location. The molecular structural requirements for triggering the latter hypothetical receptor type and potential clinical applications are discussed.

100 项与 Ferring Pharmaceuticals Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Ferring Pharmaceuticals Ltd. 相关的转化医学

登录后查看更多信息